MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Buys $101,053.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc purchased 72,700 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were purchased at an average cost of $1.39 per share, with a total value of $101,053.00. Following the completion of the purchase, the chief executive officer owned 976,121 shares in the company, valued at $1,356,808.19. This trade represents a 8.05% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

MAIA Biotechnology Trading Up 4.9%

MAIA stock opened at $1.50 on Friday. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19. The company has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.53. The stock has a market cap of $91.20 million, a PE ratio of -2.24 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Sell-side analysts forecast that MAIA Biotechnology, Inc. will post -0.52 EPS for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

Several large investors have recently added to or reduced their stakes in MAIA. Geode Capital Management LLC boosted its position in MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after buying an additional 7,746 shares during the period. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter valued at about $29,000. Jane Street Group LLC purchased a new stake in MAIA Biotechnology in the 2nd quarter valued at about $52,000. Ritholtz Wealth Management purchased a new stake in MAIA Biotechnology in the 4th quarter valued at about $35,000. Finally, Centric Wealth Management boosted its position in MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after buying an additional 11,500 shares during the period. 5.65% of the stock is owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.